ACERUS OTC Stock Financials

ASPCF -  USA Stock  

USD 0.02  0.01  33.33%

Understanding current and past ACERUS PHARMACEUTICALS Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ACERUS PHARMACEUTICALS's financial statements are interrelated, with each one affecting the others. For example, an increase in ACERUS PHARMACEUTICALS's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of ACERUS PHARMACEUTICALS's financials over time to get the whole picture.
.
We suggest to use ACERUS PHARMACEUTICALS fundamental analysis to find out if markets are at this time mispricing the company. Put another way you can use it to find out if ACERUS PHARMACEUTICALS is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to break down twenty-one available fundamental indicators for ACERUS PHARMACEUTICALS CORP, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all ACERUS PHARMACEUTICALS financials, including its cash and equivalents, number of employees, and the relationship between the gross profit and current ratio . As ACERUS PHARMACEUTICALS appears to be a penny stock we also recommend to validate its cash and equivalents numbers. Use ACERUS PHARMACEUTICALS to protect your portfolios against small market fluctuations. The stock experiences a very speculative downward sentiment. The market maybe over-reacting. Check odds of ACERUS PHARMACEUTICALS to be traded at $0.019 in 90 days.

ACERUS Fundamentals 

 
Refresh
With this module, you can analyze ACERUS financials for your investing period. You should be able to track the changes in ACERUS PHARMACEUTICALS individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Chance Of Financial Distress
Over 62
ACERUS PHARMACEUTICALS CORP has more than 62 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for ACERUS PHARMACEUTICALS otc stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in ACERUS PHARMACEUTICALS's official financial statements usually reflect ACERUS PHARMACEUTICALS's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ACERUS PHARMACEUTICALS. For example, before you start analyzing numbers published by ACERUS accountants, it's critical to develop an understanding of what ACERUS PHARMACEUTICALS's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of ACERUS PHARMACEUTICALS's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ACERUS PHARMACEUTICALS's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ACERUS PHARMACEUTICALS's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ACERUS PHARMACEUTICALS CORP. Please utilize our Beneish M Score to check the likelihood of ACERUS PHARMACEUTICALS's management to manipulate its earnings.

ACERUS PHARMACEUTICALS Company Summary

ACERUS PHARMACEUTICALS competes with Catalent. Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for mens and womens health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism Estrace, an oral tablet for the symptomatic relief of menopausal symptoms and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness and Elegant pH, a pH balanced vaginal product and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
InstrumentUSA OTC Stock View All
ExchangeOTC Exchange
Business Address2486 Dunwin Drive
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
BenchmarkDOW
Websitewww.aceruspharma.com
Phone416 679 0771
CurrencyUSD - US Dollar
You should never invest in ACERUS PHARMACEUTICALS without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of ACERUS OTC Stock, because this is throwing your money away. Analyzing the key information contained in ACERUS PHARMACEUTICALS's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

ACERUS PHARMACEUTICALS Key Financial Ratios

Generally speaking, ACERUS PHARMACEUTICALS's financial ratios allow both analysts and investors to convert raw data from ACERUS PHARMACEUTICALS's financial statements into concise, actionable information that can be used to evaluate the performance of ACERUS PHARMACEUTICALS over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that ACERUS PHARMACEUTICALS reports annually and quarterly.

ACERUS Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ACERUS PHARMACEUTICALS's current stock value. Our valuation model uses many indicators to compare ACERUS PHARMACEUTICALS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ACERUS PHARMACEUTICALS competition to find correlations between indicators driving ACERUS PHARMACEUTICALS's intrinsic value. More Info.
ACERUS PHARMACEUTICALS CORP is rated second in current ratio category among related companies. It is rated second in market capitalization category among related companies creating about  52,776,119  of Market Capitalization per Current Ratio. . Comparative valuation analysis is a catch-all model that can be used if you cannot value ACERUS PHARMACEUTICALS by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ACERUS PHARMACEUTICALS's OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ACERUS PHARMACEUTICALS's earnings, one of the primary drivers of an investment's value.

ACERUS PHARMACEUTICALS Systematic Risk

ACERUS PHARMACEUTICALS's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ACERUS PHARMACEUTICALS volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was sixty with a total number of output elements of one. The Beta measures systematic risk based on how returns on ACERUS PHARMACEUTICALS correlated with the market. If Beta is less than 0 ACERUS PHARMACEUTICALS generally moves in the opposite direction as compared to the market. If ACERUS PHARMACEUTICALS Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ACERUS PHARMACEUTICALS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ACERUS PHARMACEUTICALS is generally in the same direction as the market. If Beta > 1 ACERUS PHARMACEUTICALS moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About ACERUS PHARMACEUTICALS Financials

What exactly are ACERUS PHARMACEUTICALS Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include ACERUS PHARMACEUTICALS's income statement, its balance sheet, and the statement of cash flows. Potential ACERUS PHARMACEUTICALS investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although ACERUS PHARMACEUTICALS investors may use each financial statement separately, they are all related. The changes in ACERUS PHARMACEUTICALS's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ACERUS PHARMACEUTICALS's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as ACERUS PHARMACEUTICALS is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of ACERUS grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

ACERUS PHARMACEUTICALS December 7, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of ACERUS PHARMACEUTICALS help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ACERUS PHARMACEUTICALS CORP. We use our internally-developed statistical techniques to arrive at the intrinsic value of ACERUS PHARMACEUTICALS CORP based on widely used predictive technical indicators. In general, we focus on analyzing ACERUS OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ACERUS PHARMACEUTICALS's daily price indicators and compare them against related drivers.
Information Ratio(0.019375)
Maximum Drawdown66.67
Value At Risk(25.00)
Potential Upside33.33
Please continue to Trending Equities. Note that the ACERUS PHARMACEUTICALS information on this page should be used as a complementary analysis to other ACERUS PHARMACEUTICALS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for ACERUS OTC Stock analysis

When running ACERUS PHARMACEUTICALS price analysis, check to measure ACERUS PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACERUS PHARMACEUTICALS is operating at the current time. Most of ACERUS PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of ACERUS PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ACERUS PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of ACERUS PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is ACERUS PHARMACEUTICALS's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACERUS PHARMACEUTICALS. If investors know ACERUS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACERUS PHARMACEUTICALS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ACERUS PHARMACEUTICALS is measured differently than its book value, which is the value of ACERUS that is recorded on the company's balance sheet. Investors also form their own opinion of ACERUS PHARMACEUTICALS's value that differs from its market value or its book value, called intrinsic value, which is ACERUS PHARMACEUTICALS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACERUS PHARMACEUTICALS's market value can be influenced by many factors that don't directly affect ACERUS PHARMACEUTICALS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACERUS PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine ACERUS PHARMACEUTICALS value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACERUS PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.